STOCK TITAN

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
management

Jaguar Health (NASDAQ:JAGX) has announced new employee inducement grants effective April 3, 2025. The company granted restricted stock units (RSUs) to six new employees: two employees received 3,600 RSUs each with three-year vesting periods, while four employees received 600 or 100 RSUs each with one-year vesting schedules.

Additionally, the company granted incentive stock options to a seventh employee for the purchase of up to 520 shares at an exercise price of $4.55 per share. These options vest 25% after nine months and monthly thereafter over 36 months. All grants were approved by Jaguar's Compensation Committee and are subject to continued employment.

Jaguar Health (NASDAQ:JAGX) ha annunciato nuovi incentivi per i dipendenti a partire dal 3 aprile 2025. L'azienda ha concesso unità azionarie vincolate (RSU) a sei nuovi dipendenti: due dipendenti hanno ricevuto 3.600 RSU ciascuno con un periodo di maturazione di tre anni, mentre quattro dipendenti hanno ricevuto rispettivamente 600 o 100 RSU con un piano di maturazione di un anno.

Inoltre, l'azienda ha concesso opzioni su azioni incentivanti a un settimo dipendente per l'acquisto di fino a 520 azioni a un prezzo di esercizio di $4,55 per azione. Queste opzioni maturano al 25% dopo nove mesi e mensilmente successivamente per un periodo di 36 mesi. Tutti gli incentivi sono stati approvati dal Comitato per la Compensazione di Jaguar e sono soggetti a un'occupazione continua.

Jaguar Health (NASDAQ:JAGX) ha anunciado nuevos incentivos para empleados efectivos a partir del 3 de abril de 2025. La compañía otorgó unidades de acciones restringidas (RSU) a seis nuevos empleados: dos empleados recibieron 3,600 RSU cada uno con períodos de adquisición de tres años, mientras que cuatro empleados recibieron 600 o 100 RSU cada uno con planes de adquisición de un año.

Además, la compañía otorgó opciones sobre acciones incentivadas a un séptimo empleado para la compra de hasta 520 acciones a un precio de ejercicio de $4.55 por acción. Estas opciones se adquieren al 25% después de nueve meses y mensualmente a partir de entonces durante 36 meses. Todas las concesiones fueron aprobadas por el Comité de Compensación de Jaguar y están sujetas a empleo continuo.

재규어 헬스 (NASDAQ:JAGX)는 2025년 4월 3일부터 효력이 발생하는 새로운 직원 유인 보상을 발표했습니다. 회사는 여섯 명의 신입 직원에게 제한된 주식 단위(RSU)를 부여했습니다: 두 명의 직원은 각각 3,600 RSU를 받았으며, 3년의 베스팅 기간을 가지고 있습니다. 나머지 네 명의 직원은 각각 600 또는 100 RSU를 받았으며, 1년의 베스팅 일정에 따라 부여되었습니다.

추가로, 회사는 일곱 번째 직원에게 최대 520주를 구매할 수 있는 인센티브 주식 옵션을 부여했습니다. 행사 가격은 $4.55 per share입니다. 이 옵션은 9개월 후 25%가 베스팅되고, 이후 36개월 동안 매월 베스팅됩니다. 모든 보상은 재규어의 보상 위원회에 의해 승인되었으며, 지속적인 고용에 따라 달라집니다.

Jaguar Health (NASDAQ:JAGX) a annoncé de nouvelles incitations pour les employés, effectives à partir du 3 avril 2025. L'entreprise a accordé des unités d'actions restreintes (RSU) à six nouveaux employés : deux employés ont reçu chacun 3 600 RSU avec des périodes d'acquisition de trois ans, tandis que quatre employés ont reçu respectivement 600 ou 100 RSU avec des calendriers d'acquisition d'un an.

De plus, l'entreprise a accordé des options d'achat d'actions incitatives à un septième employé pour l'achat de jusqu'à 520 actions à un prix d'exercice de $4,55 par action. Ces options acquièrent 25 % après neuf mois et mensuellement par la suite pendant 36 mois. Toutes les attributions ont été approuvées par le Comité de Rémunération de Jaguar et sont soumises à un emploi continu.

Jaguar Health (NASDAQ:JAGX) hat neue Anreize für Mitarbeiter bekannt gegeben, die ab dem 3. April 2025 wirksam werden. Das Unternehmen hat sechs neuen Mitarbeitern eingeschränkte Aktieneinheiten (RSUs) gewährt: Zwei Mitarbeiter erhielten jeweils 3.600 RSUs mit einer Vesting-Dauer von drei Jahren, während vier Mitarbeiter jeweils 600 oder 100 RSUs mit einer Vesting-Dauer von einem Jahr erhielten.

Darüber hinaus hat das Unternehmen einem siebten Mitarbeiter Anreizaktienoptionen zum Kauf von bis zu 520 Aktien zu einem Ausübungspreis von $4,55 pro Aktie gewährt. Diese Optionen vesten zu 25% nach neun Monaten und monatlich danach über einen Zeitraum von 36 Monaten. Alle Zuteilungen wurden vom Vergütungsausschuss von Jaguar genehmigt und unterliegen einer fortdauernden Beschäftigung.

Positive
  • None.
Negative
  • None.

SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / April 4, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective April 3, 2025, the Company granted 3,600 restricted stock units (RSUs) to New Employee 1, 3,600 RSUs to New Employee 2, 600 RSUs to New Employee 3, 100 RSUs to New Employee 4, 600 RSUs to New Employee 5, and 600 RSUs to New Employee 6.

The RSUs for New Employees 1 and 2 vest over three years, with one-third of the RSUs vesting each year starting from each employee's date of hire. The RSUs for New Employees 3 through 6 vest over one year starting from each employee's date of hire. The RSUs for New Employees 1 through 6 were granted as an inducement material to each employee's acceptance of employment by the Company and were approved by the Compensation Committee of Jaguar's Board. Vesting of the RSUs is subject to each new employee's continued service with Jaguar through the applicable vesting dates.

Additionally, effective April 3, 2025, the Company granted incentive stock options for the purchase of up to 520 shares of the Company's common stock to New Employee 7 as an inducement award under the Company's Inducement Award Plan. The incentive stock options have an exercise price of $4.55 per share, representing the closing price of Jaguar's common stock as reported by Nasdaq on the grant date. The incentive stock option award vests 25% at nine (9) months from New Employee 7's date of hire, and vests monthly thereafter over 36 months. The incentive stock options were granted as an inducement material to New Employee 7's acceptance of employment with the Company and were approved by the Compensation Committee of the Board. Vesting of the incentive stock options is subject to New Employee 7's continued service with Jaguar through the applicable vesting dates.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit www.napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Source: Jaguar Health, Inc.

Contact:

hello@jaguar.health

Jaguar-JAGX

SOURCE: Jaguar Health, Inc.



View the original press release on ACCESS Newswire

FAQ

How many RSUs did Jaguar Health (JAGX) grant in their April 2025 inducement awards?

Jaguar Health granted a total of 9,100 RSUs across six new employees, with individual grants ranging from 100 to 3,600 RSUs.

What is the vesting schedule for JAGX's April 2025 RSU grants?

Two employees have three-year vesting periods (one-third per year), while four employees have one-year vesting periods from their hire dates.

What is the exercise price for JAGX's April 2025 incentive stock options?

The incentive stock options were granted at $4.55 per share, matching Jaguar's closing price on Nasdaq on April 3, 2025.

What are the vesting terms for JAGX's April 2025 incentive stock options?

The options vest 25% after nine months, followed by monthly vesting over 36 months, subject to continued employment.
Jaguar Health Inc

NASDAQ:JAGX

JAGX Rankings

JAGX Latest News

JAGX Stock Data

2.98M
576.85k
14.81%
1.71%
5.81%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN FRANCISCO